{"ticker": {"uuid": "2267fd78-d0c3-4f92-9fe9-4762f8272966", "symbol": "IVX", "name": "Invion Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Invion Limited (ASX:IVX): How Is This Photodynamic Therapy Biotech Advancing Its Cancer and Infection Pipeline?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPX0hkZm9BZGd4NVk0dHNDQXJxWlZuVElhRXVZX0ZER3ctMDNlWXRkeUUtUDVaUXZ1UENQR19PXzdyYkZ6TUtzbG5lSzBUS2tDQUc1dGxZQ1FFc1J2dGJCdnNfWEpwdENicnhwRjRzZ29lQWZtOEVBVDlWek1sNlQzSUR4bm9YNWNiWlpUQlZhTjFOdERNNHltdk00VmF1MFotWEhlT0xyQUYwMmQzZzI1bmZlQlZyWUlnSHpJQkk2S3k4N3hhUlUyOGo3YV91RFlIc1hqNlJJdDZYb09qc0NKTnUzS053Zw?oc=5", "source_name": "Kalkine", "published_at": "2026-07-10T01:29:00+00:00", "published_display": "10 Jul 2026 01:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invion Ltd Share Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE0wT0lCenRpRW42VlVyTVQ0NnZjNFlIWi1TX0pOWDh6aFdBQXNBNkw2LVQ0VXR1bEdhbkNmS2FsT1UzQVVTVmQ2SFNkeEptbExyNnZ5UjdydjlKeURtR0xoN24zb0pqZw?oc=5", "source_name": "CMC Markets", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Health Check: Invion eyes new angle on Opthea trial flop", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQMkNMWlF2bjBPTUdkdmVZRVdtWkljVFRfbmxiSHZnY3d4ci1mMkczUzliemFpeGR0dTF4SjdwWm9BaElKX3pPNjB3dmIyS0FoN3Q4Vk1xcThnemhkNWtzcHA1UmRJRXNHYUVlamVPaFh5aGp1dDJWUTRmRUhCdFBJUVdzRG5JYzhhQUtHTVFPalA1YXN6UmRHbTFjLUpXeDg?oc=5", "source_name": "Stockhead", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invion Limited (ASX: IVX) Faces Funding and Clinical Development Challenges at Depressed Valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNZ1RWejFEeHJOWmFsMHl5eHd1am1Na2VkU08xRFdKdkExelQwc0NwdDdUWFMwTjRtSHFiOVJubVNTdUxBYXdaOWd5Q0ZzWDhveGU4MTFzUUZsamhwUjRXakdDMHVMZ3U2aFNKcms3ajI0UTgyNG1uVkVKR0g0SmFNWVhzTXpCUFVtTjBqa1pHaFBhR1ZCRnRDSUdNTWY0eW1WV0t0Q25pcjFobldrTEVRNHJWY2M2Ui1fXzlkNGtOYlZrY2tnVXA0NEtWQ2lXSWc?oc=5", "source_name": "Kalkine", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korean partner backs Invion\u2019s INV043 ahead of Australia first-in-human trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxQOGVxNUxrc2RWWFNoc3RIQmR2RFU3NHRuYnZnU3RVdnRGQkx4YjdQcDY1Wm92cmNwQnNPbEtlNWRRMmVRVkl2aGNFWTU5c3oxTC01Y2VfeS1NY3AtSFhQNk9fODJ2SUtBUUw3SVJyWHp4b0RhaVJHY1h3SU9iNVFuMHRqUHk4TXpCcWFYOEFIZWVUWVo2V296OW13V3lzajlQUTB1cktzdzRabG1IbEtzRDBHc1ZkRlU1ODM3NUVnWlY1a2dReldSWXdoMGk1TkwxNkk0WEJ4WkJvN1o0QUNoNng1ZjZGaVpHcVhlLWdDVQ?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Invion Ltd (ASX:IVX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE5qeXcyd0ZVMEd6ZnUwdndKZVVOZ05sMGo2cDFORE0yZkJZd3NIMzZuaVpGVkZJV2hXSlhyX0E0cUhTN1M2R0RJYWh2dVdTYi0x?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T17:58:39+00:00", "published_display": "30 Oct 2025 17:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invion Limited Announces Director\u2019s Change in Share Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNMkZ5WW95NEI0ZGlEekZQbmRlSWo4cnBMdy13eUw1Y0RsX1Boa3ZLR1doRjRFN0d5ajJVd0dseVo3Z2FOeDhJMlJKaVFqQk84ZWd1bDBzX2ZodGlVek9HektsZHgxV3JMS0drOFRxTlE5U1c5bzluSUlnbU1lZG9pVEtZVVFPdHgxVUtmZ0NZcm5HSkticFVOd19ETkhSMmpzU3RWTFZ2MFNhZzZ1R0hn?oc=5", "source_name": "TipRanks", "published_at": "2025-07-23T07:00:00+00:00", "published_display": "23 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invion: Revolutionizing Photodynamic Therapy (PDT) for Cancer, Infectious Diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNb1BLb3dNSUtBaTZicjNiaTByT09iM3VoNVRyelFtazNsck9xQUxTOVh1TG0tU3JIOUlZdDZ0TUZhS2RBdWNqQUFPYm42Ni11TTd3NFhQRVdLeC1DUU9YX3BmaTd4cDVneTVXd3JzdXF5OUxsZ1pxbXRhR0tsempZeGtkNFhhT0tFQVY4bjlrX3Y4akljOENOZnZyTkowRERvbnc4U2djRGk?oc=5", "source_name": "Investing News Network", "published_at": "2025-04-14T07:00:00+00:00", "published_display": "14 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALERT: Price-sensitive ASX Announcement for IVX", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNVlpvR1VMY1VTZUxxWmxhYl9ZWkZ3UVRPT3BMX2s4UElXMkg4NjRWdGtQZ1lFM2pvclN3dUFWVFRlOWFMOS1KdFhfZjNrSFRoQ3hQT0ZVLTNTNlJxU2xtY1RIWk92VTdwcC01MndaUlRmaTFPdnRzMmQ4YmcwY3VQZ052QUlBQUIzR29YaTZIYU5KcUlnajQtRkV1TTNHc0pXS05ILXQ1UGdUWE1GYkc0cDN3?oc=5", "source_name": "intelligentinvestor.com.au", "published_at": "2024-10-24T22:37:53+00:00", "published_display": "24 Oct 2024 22:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invion share price (ASX:IVX) rockets 123% on pilot study results", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQbS1RcHZGa25ZWTU2SXV0aHlwSWVhNEt1RW1TdkxTVkhNU29TNXFqMnBjbHYzTFNkMnpxaUF4NC1KSlgzd01zWTZrRGx4cE82VmdqSm9LWGdMcU9JUFBVRnlueEdwNmdrWEplSF9zRG0tMnFmRVVPVm1CTGZqRUREMWZLQWRycFdoY09vZnVURjVnMFF1QVNDZ01mTmQ?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2021-10-28T07:00:00+00:00", "published_display": "28 Oct 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Invion Limited (ASX:IVX): How Is This Photodynamic Therapy Biotech Advancing Its Cancer and Infection Pipeline?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPX0hkZm9BZGd4NVk0dHNDQXJxWlZuVElhRXVZX0ZER3ctMDNlWXRkeUUtUDVaUXZ1UENQR19PXzdyYkZ6TUtzbG5lSzBUS2tDQUc1dGxZQ1FFc1J2dGJCdnNfWEpwdENicnhwRjRzZ29lQWZtOEVBVDlWek1sNlQzSUR4bm9YNWNiWlpUQlZhTjFOdERNNHltdk00VmF1MFotWEhlT0xyQUYwMmQzZzI1bmZlQlZyWUlnSHpJQkk2S3k4N3hhUlUyOGo3YV91RFlIc1hqNlJJdDZYb09qc0NKTnUzS053Zw?oc=5", "source_name": "Kalkine", "published_at": "2026-07-10T01:29:00+00:00", "published_display": "10 Jul 2026 01:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invion Ltd Share Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE0wT0lCenRpRW42VlVyTVQ0NnZjNFlIWi1TX0pOWDh6aFdBQXNBNkw2LVQ0VXR1bEdhbkNmS2FsT1UzQVVTVmQ2SFNkeEptbExyNnZ5UjdydjlKeURtR0xoN24zb0pqZw?oc=5", "source_name": "CMC Markets", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Health Check: Invion eyes new angle on Opthea trial flop", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQMkNMWlF2bjBPTUdkdmVZRVdtWkljVFRfbmxiSHZnY3d4ci1mMkczUzliemFpeGR0dTF4SjdwWm9BaElKX3pPNjB3dmIyS0FoN3Q4Vk1xcThnemhkNWtzcHA1UmRJRXNHYUVlamVPaFh5aGp1dDJWUTRmRUhCdFBJUVdzRG5JYzhhQUtHTVFPalA1YXN6UmRHbTFjLUpXeDg?oc=5", "source_name": "Stockhead", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invion Limited (ASX: IVX) Faces Funding and Clinical Development Challenges at Depressed Valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNZ1RWejFEeHJOWmFsMHl5eHd1am1Na2VkU08xRFdKdkExelQwc0NwdDdUWFMwTjRtSHFiOVJubVNTdUxBYXdaOWd5Q0ZzWDhveGU4MTFzUUZsamhwUjRXakdDMHVMZ3U2aFNKcms3ajI0UTgyNG1uVkVKR0g0SmFNWVhzTXpCUFVtTjBqa1pHaFBhR1ZCRnRDSUdNTWY0eW1WV0t0Q25pcjFobldrTEVRNHJWY2M2Ui1fXzlkNGtOYlZrY2tnVXA0NEtWQ2lXSWc?oc=5", "source_name": "Kalkine", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korean partner backs Invion\u2019s INV043 ahead of Australia first-in-human trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxQOGVxNUxrc2RWWFNoc3RIQmR2RFU3NHRuYnZnU3RVdnRGQkx4YjdQcDY1Wm92cmNwQnNPbEtlNWRRMmVRVkl2aGNFWTU5c3oxTC01Y2VfeS1NY3AtSFhQNk9fODJ2SUtBUUw3SVJyWHp4b0RhaVJHY1h3SU9iNVFuMHRqUHk4TXpCcWFYOEFIZWVUWVo2V296OW13V3lzajlQUTB1cktzdzRabG1IbEtzRDBHc1ZkRlU1ODM3NUVnWlY1a2dReldSWXdoMGk1TkwxNkk0WEJ4WkJvN1o0QUNoNng1ZjZGaVpHcVhlLWdDVQ?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Invion Ltd (ASX:IVX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE5qeXcyd0ZVMEd6ZnUwdndKZVVOZ05sMGo2cDFORE0yZkJZd3NIMzZuaVpGVkZJV2hXSlhyX0E0cUhTN1M2R0RJYWh2dVdTYi0x?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T17:58:39+00:00", "published_display": "30 Oct 2025 17:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invion Limited Announces Director\u2019s Change in Share Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNMkZ5WW95NEI0ZGlEekZQbmRlSWo4cnBMdy13eUw1Y0RsX1Boa3ZLR1doRjRFN0d5ajJVd0dseVo3Z2FOeDhJMlJKaVFqQk84ZWd1bDBzX2ZodGlVek9HektsZHgxV3JMS0drOFRxTlE5U1c5bzluSUlnbU1lZG9pVEtZVVFPdHgxVUtmZ0NZcm5HSkticFVOd19ETkhSMmpzU3RWTFZ2MFNhZzZ1R0hn?oc=5", "source_name": "TipRanks", "published_at": "2025-07-23T07:00:00+00:00", "published_display": "23 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invion: Revolutionizing Photodynamic Therapy (PDT) for Cancer, Infectious Diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNb1BLb3dNSUtBaTZicjNiaTByT09iM3VoNVRyelFtazNsck9xQUxTOVh1TG0tU3JIOUlZdDZ0TUZhS2RBdWNqQUFPYm42Ni11TTd3NFhQRVdLeC1DUU9YX3BmaTd4cDVneTVXd3JzdXF5OUxsZ1pxbXRhR0tsempZeGtkNFhhT0tFQVY4bjlrX3Y4akljOENOZnZyTkowRERvbnc4U2djRGk?oc=5", "source_name": "Investing News Network", "published_at": "2025-04-14T07:00:00+00:00", "published_display": "14 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALERT: Price-sensitive ASX Announcement for IVX", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNVlpvR1VMY1VTZUxxWmxhYl9ZWkZ3UVRPT3BMX2s4UElXMkg4NjRWdGtQZ1lFM2pvclN3dUFWVFRlOWFMOS1KdFhfZjNrSFRoQ3hQT0ZVLTNTNlJxU2xtY1RIWk92VTdwcC01MndaUlRmaTFPdnRzMmQ4YmcwY3VQZ052QUlBQUIzR29YaTZIYU5KcUlnajQtRkV1TTNHc0pXS05ILXQ1UGdUWE1GYkc0cDN3?oc=5", "source_name": "intelligentinvestor.com.au", "published_at": "2024-10-24T22:37:53+00:00", "published_display": "24 Oct 2024 22:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invion share price (ASX:IVX) rockets 123% on pilot study results", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQbS1RcHZGa25ZWTU2SXV0aHlwSWVhNEt1RW1TdkxTVkhNU29TNXFqMnBjbHYzTFNkMnpxaUF4NC1KSlgzd01zWTZrRGx4cE82VmdqSm9LWGdMcU9JUFBVRnlueEdwNmdrWEplSF9zRG0tMnFmRVVPVm1CTGZqRUREMWZLQWRycFdoY09vZnVURjVnMFF1QVNDZ01mTmQ?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2021-10-28T07:00:00+00:00", "published_display": "28 Oct 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 61, "total_relevant": 10, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 10, "score": 50, "total": 10, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 92, "events": [{"event": "general", "label": "Market update", "weight": 4.95, "count": 9}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.04, "latest_week": "2026-07-10", "one_week_move": 15.6, "four_week_move": -15.9, "twelve_week_move": -37.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.338212, "market_dynamics_buy_signal": false, "relative_strength": -54.882836, "fair_value_gap": -86.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 26.7027, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+15.6% over one week, -15.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Kalkine", "count": 2}, {"label": "smallcaps.com.au", "count": 2}, {"label": "CMC Markets", "count": 1}, {"label": "Stockhead", "count": 1}, {"label": "TipRanks", "count": 1}, {"label": "Investing News Network", "count": 1}, {"label": "intelligentinvestor.com.au", "count": 1}, {"label": "The Motley Fool Australia", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 10}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 9}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "92/100 classification confidence."}, {"label": "Company focus", "value": "10", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+15.6% over one week, -15.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Invion Limited (ASX:IVX): How Is This Photodynamic Therapy Biotech Advancing Its Cancer and Infection Pipeline?"}], "updated_at": "2026-07-17T15:33:22.589954+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}